ALNY

As of 2026-09-10, ALNY scores 47out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ALNY trades at $247.51, within its fair-value band.

ALNY scores 47 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 47. Its strongest factor is quality at 69 (strong), where earnings quality and balance-sheet strength stand out, followed by value at 55. The weakest is momentum at 25, where price trend is the soft spot. Among Healthcare stocks it ranks in roughly the top 47% of the Healthcare names the model scores.

On valuation, ALNY is priced in the upper part of its recent range. The blended composite before the macro overlay was 49. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on ALNY, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ALNY sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ALNY runs $161.01–$288.19. Current price $247.51 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.